$16.58
2.59% today
Nasdaq, Dec 30, 10:00 pm CET
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Arcturus Therapeutics Ltd Target price 2024 - Analyst rating & recommendation

Arcturus Therapeutics Ltd Classifications & Recommendation:

Buy
100%

Arcturus Therapeutics Ltd Price Target

Target Price $79.47
Price $16.58
Potential
Number of Estimates 9
9 Analysts have issued a price target Arcturus Therapeutics Ltd 2025 . The average Arcturus Therapeutics Ltd target price is $79.47. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 10 Analysts recommend Arcturus Therapeutics Ltd to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Arcturus Therapeutics Ltd stock has an average upside potential 2025 of . Most analysts recommend the Arcturus Therapeutics Ltd stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 157.75 175.45
23.42% 11.22%
EBITDA Margin -0.76% -54.08%
108.29% 7,009.27%
Net Margin -19.23% -41.13%
517.88% 113.92%

10 Analysts have issued a sales forecast Arcturus Therapeutics Ltd 2024 . The average Arcturus Therapeutics Ltd sales estimate is

$175m
Unlock
. This is
20.50% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$221m 51.87%
Unlock
, the lowest is
$140m 4.19%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $158m 23.42%
2024
$175m 11.22%
Unlock
2025
$214m 21.90%
Unlock
2026
$334m 56.10%
Unlock
2027
$505m 51.16%
Unlock
2028
$760m 50.54%
Unlock

2 Analysts have issued an Arcturus Therapeutics Ltd EBITDA forecast 2024. The average Arcturus Therapeutics Ltd EBITDA estimate is

$-94.9m
Unlock
. This is
252.33% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-92.3m 242.62%
Unlock
, the lowest is
$-97.5m 262.05%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-1.2m 106.35%
2024
$-94.9m 7,806.94%
Unlock
2025
$-138m 45.94%
Unlock
2026
$-120m 13.23%
Unlock

EBITDA Margin

2023 -0.76% 108.29%
2024
-54.08% 7,009.27%
Unlock
2025
-64.74% 19.71%
Unlock
2026
-35.99% 44.41%
Unlock

2 Arcturus Therapeutics Ltd Analysts have issued a net profit forecast 2024. The average Arcturus Therapeutics Ltd net profit estimate is

$-72.2m
Unlock
. This is
20.59% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-59.3m 0.90%
Unlock
, the lowest is
$-85.0m 42.08%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-30.3m 420.00%
2024
$-72.2m 137.95%
Unlock
2025
$-108m 49.72%
Unlock
2026
$-50.2m 53.54%
Unlock

Net Margin

2023 -19.23% 517.88%
2024
-41.13% 113.92%
Unlock
2025
-50.52% 22.83%
Unlock
2026
-15.04% 70.23%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.12 -2.67
420.00% 138.39%
P/E negative
EV/Sales 1.13

2 Analysts have issued a Arcturus Therapeutics Ltd forecast for earnings per share. The average Arcturus Therapeutics Ltd <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.67
Unlock
. This is
20.81% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.19 0.90%
Unlock
, the lowest is
$-3.14 42.08%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.12 420.00%
2024
$-2.67 138.39%
Unlock
2025
$-3.99 49.44%
Unlock
2026
$-1.85 53.63%
Unlock

P/E ratio

Current -7.69 187.69%
2024
-6.39 16.91%
Unlock
2025
-4.27 33.18%
Unlock
2026
-9.18 114.99%
Unlock

Based on analysts' sales estimates for 2024, the Arcturus Therapeutics Ltd stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.36 27.66%
2024
1.13 16.91%
Unlock
2025
0.93 17.96%
Unlock
2026
0.59 35.93%
Unlock
2027
0.39 33.84%
Unlock
2028
0.26 33.57%
Unlock

P/S ratio

Current 3.17 9.50%
2024
2.63 17.02%
Unlock
2025
2.16 17.96%
Unlock
2026
1.38 35.94%
Unlock
2027
0.91 33.85%
Unlock
2028
0.61 33.57%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today